decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2003 / AB-03-130
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a CMS Program Memorandum that updates Medicare payment and billing instructions for intravenous levocarnitine when used in the ESRD setting. It is relevant to dialysis providers, billing staff, and coders who need to understand the coverage context, claim-form instructions, and effective/implementation timing described in the memorandum.
Why This Topic Matters
It explains a Medicare coverage update that affects how ESRD facilities and carriers handle claims for a specific drug therapy, including the billing formats and claim-reporting elements referenced by the memorandum.
Article Sections
-
General Information
Overview of the memorandum’s purpose, scope, and the ESRD-related coverage context addressed by CMS.
-
Billing Requirements
Claim-processing and billing guidance for intermediaries and carriers, including form and reporting references tied to the memorandum.
-
Medicare Summary Notices (MSN) and Remittance Advice
The MSN language referenced for denied claims and the timing information associated with the memorandum.
What You Will Learn
- The Medicare coverage context addressed by the memorandum
- The types of claim-processing guidance included for ESRD-related billing
- The forms and administrative references used for reporting
- The effective and implementation timing discussed in the memorandum
Who Should Read This
- ESRD facility billers
- Medical coders
- Revenue cycle staff
- Medicare claims processing staff
- Dialysis provider administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com